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Background. The synthetic triterpenoid 2-Cyano-3,12-Dioxooleana-1,9-Dien-28-Oic Acid (CDDO) and derivatives display anti-
tumor activity against a variety of cultured tumor cell lines and in mouse xenografts. In this report, we have studied the effects
of CDDO and its imidazolide derivative (CDDO-Im) on chronic lymphocytic leukemia (CLL), using patients’ CLL cells and a mouse
model of CLL and small B cell lymphoma (SBL). Principal Findings. CDDO and CDDO-Im efficiently induced apoptosis of
malignant human and mouse B-cells ex vivo, although CDDO-Im was over 10-fold more potent than CDDO. Treating mice with
CLL/SBL with liposome-formulated CDDO or CDDO-Im resulted in significant reductions of B cells in blood, spleen and lung.
CDDO-Im was shown to be more potent than CDDO, while treatment with empty liposomes had no impact on disease. CDDO-
Im treatment initially resulted in an increase of circulating B cells, which correlates with a reduction in resident lymphocytes in
spleen, and lungs, suggesting that CDDO-Im induces mobilization of tumor cells from lymphoid organs and infiltrated tissues
into the circulation. Analysis of blood cells recovered from treated mice also showed that CDDO-Im is a potent inducer of
tumor cells death in vivo. Furthermore, CDDO-Im efficiently eradicated mouse CLL/SBL cells but had little effect on the viability
of normal B and T cells in vivo. Significance. The presented data demonstrate that triterpenoids CDDO and CDDO-Im reduce
leukemia and lymphoma burden in vivo in a transgenic mouse model of CLL/SBL, and support the clinical testing of CDDO-
based synthetic triterpenoids in patients with CLL.
Citation: Kress CL, Konopleva M, Martı ´nez-Garcı ´a V, Krajewska M, Lefebvre S, et al (2007) Triterpenoids Display Single Agent Anti-tumor Activity in
a Transgenic Mouse Model of Chronic Lymphocytic Leukemia and Small B Cell Lymphoma. PLoS ONE 2(6): e559. doi:10.1371/journal.pone.0000559
INTRODUCTION
Chronic Lymphocytic Leukemia (CLL) is the most common
leukemia in the western world, and it is characterized by the
gradual accumulation of quiescent, apoptosis resistant, B cells
[1,2]. No cure is available at this time for this disease, although the
current therapies involving the use of chemotherapeutical drugs,
such as the purine analog F-ara-A, have proven helpful for some
patients. However, a significant number of patients will eventually
develop refractory disease as a result of the emergence of leukemic
clones resistant to drugs, leading to patient demise [3,4].
Consequently, new therapies are necessary for treating patients
with refractory disease. However, the absence of cell lines derived
from CLL patients that can propagate in mice, and the lack of
mouse models of CLL that recapitulate the human disease have
hampered the preclinical development of new therapies and
treatment strategies for this disease.
Overexpression of both Bcl-2 and TRAF1 is a hallmark of
human CLL cells [5,6]. Bcl-2 overexpression largely accounts for
the apoptosis resistant phenotype of CLL cells [5]. TRAF1 is
frequently overexpressed in CLL cells from patients with re-
fractory disease, suggesting that TRAF1 might be involved in
disease progression [7]. Indeed, mice overexpressing in B cells
both a TRAF2 mutant that mimics TRAF1 and Bcl-2 develop
Small B-cell Lymphoma (SBL) and Chronic Lymphocytic
Leukemia (CLL) with high incidence [8]. This TRAF2 mutant
consists of only the TRAF domain and thus, like TRAF1, is devoid
of the RING and zinc finger domains found in other members of
the TRAF family [9]. Furthermore, CLL/SBL cells from the
TRAF2DN/Bcl-2 mice are resistant to chemotherapeutic drugs,
such as dexamethasone and F-ara-A [8]. Altogether, the CLL
developed by these mice recapitulates many aspects of refractory
CLL disease in humans, and as such, this CLL mouse model might
be suitable as preclinical model for testing new drugs for CLL.
Triterpenoids, such as oleanolic acid and ursolic acid, are
natural compounds with anti-tumorigenic and anti-inflammatory
properties [10]. Synthetic triterpenoid derivatives such as 2-
Cyano-3,13 dioxooleana-1,9(11)-dien-28-oic acid (CDDO) [11]
and its derivative 1-[2-cyano -3-,12-dioxooleana-1,9(11)-dien-28-
oyl]imidazole (CDDO-Im) [12] have more potent anti-tumoral
activity compared to the natural compounds. Thus, they efficiently
inhibit tumor cell proliferation [13–18] and induce apoptosis of
a variety of epithelial tumor cell lines [13,16,19–22] , lymphoid
cell lines and patient-derived leukemia specimens [17,23–27].
Interestingly, CDDO and CDDO-Im have been shown to
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resistant to conventional therapies with little effect on the viability
of normal cells [26,28]. Triterpenoids also restore the sensitivity of
resistant tumor cells to TRAIL [19,21], TNF [27,29] and
chemotherapeutic drugs [26], and are well tolerated by mice
[13,14,18,21].
The current evidence suggests that synthetic triterpenoids have
a variety of effects on apoptosis pathways, which might be different
depending on the cell-type under investigation. In this regard,
triterpenoids have been shown to induce depletion of mitochon-
drial glutathione [22,28,30], to inhibit mitochondria electron
transport [22,23,26,28,31], to increase the concentration of
reactive oxygen species [22,28], to inhibit NFkB activation
[27,29,32], to downregulate FLIP [19,21,28,33] and upregulate
TNF-family Death Receptors [20,21,30], resulting in cell death by
activation of caspase-dependent [20,23–26,28,29,33,34] and in-
dependent [24] cell death pathways.
In this report, we used TRAF2DN/Bcl-2 mice that have
developed CLL/SBL as a preclinical model to test the efficacy of
CDDO and CDDO-Im against CLL cells, both ex vivo and in vivo.
MATERIALS AND METHODS
Transgenic mice
Transgenic mice expressing both Bcl-2 and a TRAF2 deletion
mutant lacking the N-terminal 240 amino-acids encompassing the
RING and zinc finger domains (TRAF2DN) have been described
[8]. Bcl-2 (Balb/c) and TRAF2DN (FVB/n) heterozygous mice
were bred to produce TRAF2DN/Bcl-2 double-positive mice.
Mouse genotyping was performed by PCR analysis using primers
specific for human Bcl-2 and TRAF2DN.
Cell isolation
Mouse spleens were carefully crushed to release the lymphocytes.
Blood was collected from the cavernous sinus and collected in tubes
coated with heparin. The animal protocols were approved by the
Institutional Animal Care and Use Committee. Euthanasia was
performed by following the rules of the American Veterinarian
Medical Association. Patient CLL cells were obtained from the
Chronic Lymphocytic Leukemia Research Consortium (CRC)
(MooresCancerCenter,Universityof CaliforniaSanDiego,La Jolla,
CA).DonationsofCLLsamplestoCRCrequirethewrittenconsentof
the patients in compliance with the Declaration of Helsinki.
Liposome production
CDDO and CDDO-Im were formulated in liposomes at
a concentration of 2 mg/ml as described [18]. Briefly, triterpe-
noids (CDDO and CDDO-Im) were solubilized in t-butanol at
37uC at a concentration of 2 mg/ml. Phospholipid distearoyl
phosphatidyl choline (DSPC) was solubilized in t-butanol at 55uC,
at a concentration of 10 mg/ml. DSPC and either CDDO or
CDDO-Im were then mixed together and frozen. The lipid/drug
ratio used was 20:1. Liposomes containing triterpenoids were
lyophilized overnight and then reconstituted in normal saline at
55uC, and centrifuged at 13,000 rpm for 1 hour. Pellets were
resuspended at room temperature in normal saline at a concen-
tration of 2 mg/ml (100 mM) for the in vivo studies. Empty
liposomes were made using the same lipids and following the same
protocol, but without adding triterpenoids.
Drug administration
TRAF2DN/Bcl-2 mice were injected into the tail vein with empty
liposomes or liposomes containing either CDDO or CDDO-Im, at
5, 10 or 20 mg/kg per dosage (corresponding to 17.3, 34.5 and
69 mg/m
2/dosage, respectively). Each mouse received nine
injections administered over a period of 21–25 days. The
concentration of B cells in blood was monitored every other day
after inoculations, and 3 to 10 days after the final inoculation.
Quantification of B and T cells in blood
Blood was collected in heparinized capillary tubes and diluted 5
times in PBS containing 10% FCS, 1% BSA, 0.05% sodium azide,
5 mM EDTA and 50 mg/ml of human c-globulin and incubated
for 15 min at RT. Then, the mixture was incubated with anti-
CD45 PE-Cy5 and either anti-B220 PE, anti-CD4 PE or the
respective isotype controls, and incubated for 20 min at RT.
Erythrocytes were lysed using 10 volumes of hypotonic lysis buffer
(PharMlyse, BD biosciences) and quantification was performed on
a personal cell analysis and counter-top microfluorocytometer
(Guava technologies, Hayward, CA).
Flow cytometry
Cell suspensions were depleted of red cells and neutrophils by
density centrifugation (Lympholite-M, Cedarlane laboratories,
Hornby, Ontario). Lymphocytes were incubated with 50 mg/ml
human c-globulin to block Fc-receptors. Then 10
5 to 5610
6 cells
were incubated with a combination of allophycocyanin (APC)-,
fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-conju-
gated antibodies recognizing various surface markers. After 1h
incubation at 4uC, cells were washed in high glucose DMEM
(without phenol red) (Irvine Scientific, Santa Ana, CA) containing
3% FCS (Hyclone, Logan, UT). Flow cytometry analysis was
accomplished using a FACScalibur equipped with detectors for 4
colors (BD biosciences, San Jose, CA).
Cell viability
CLL cells from human patients were incubated ex vivo with or
without triterpenoids. Cells were harvested after 24 h, washed,
incubated with Annexin-V-FITC and propidium iodide (PI), and
analyzed by flow cytometry. In the case of mouse splenocytes, cells
were harvested 24 h after the addition of the drugs to cells. Then,
cells were incubated with APC-anti-B220 mAb for 30 min,
washed and incubated with Annexin-V-FITC and PI and then
analyzed by flow cytometry.
Viability of blood leukocytes was determined as follows: blood
(20 ml) was collected from the cavernous sinus and immediately
mixed with 80 ml of PBS containing 10% FCS, 1% BSA, 0.05%
sodium azide, and 5 mM EDTA. Then, 15 ml of this mixture was
subjected to hypotonic lysis with 250 ml of PharM Lyse (BD-
biosciences). After incubation for 20 minutes, cells were recovered
by centrifugation for 5 minutes at 2,500 rpm, and the resulting cell
pellet was resuspended in 200 ml of Guava ViaCount reagent
(Guava Technologies) and incubated in the dark for 20 minutes.
Fluorometry assay was performed using the Guava PCA-96
microfluorometer.
Immunohistochemistry
Tissues and organs from transgenic mice of the various genotypes
were fixed in Z-fix solution (Anatech Ltd, Hayward, CA) and
embedded in paraffin. Tissue sections (5 mm) were stained with
hematoxylin and eosin (H&E).
RESULTS
To test whether triterpenoids CDDO and CDDO-Im (Figure 1)
induce apoptosis of human and mouse CLL cells ex vivo, CLL cells
Anti-CLL Activity of CDDO-Im
PLoS ONE | www.plosone.org 2 June 2007 | Issue 6 | e559Figure 1. Chemical structures of CDDO and CDDO-imidazolide. The synthesis of CDDO and CDDO-Im was previously described [11,12].
doi:10.1371/journal.pone.0000559.g001
Figure 2. Effects of CDDO and CDDO-Im on apoptosis of human CLL and TRAF2DN/Bcl-2 cells. Human CLL cells (A) and splenocytes isolated from
TRAF2DN/Bcl-2 transgenic mice (B) were cultured with or without CDDO and CDDO-Im at the indicated concentrations. Human CLL cells (n=4) were
obtained from 2 patients previously untreated with standard therapies (e and X), one patient refractory to chlorambucil (&) and one patient
refractory to F-ara-A (D). Cells were harvested after 24 h, washed and incubated with Annexin-V-FITC and PI. Mouse splenocytes (n=6) were also
harvested after 24 h, but first they were incubated with APC-anti-B220 mAb for 30 min, then washed and incubated with Annexin-V-FITC and PI.
Lymphocytes (A) or B lymphocytes (B220
+ cells) (B) were gated and the percentage of apoptotic cells (Annexin V
+) was determined by flow
cytometry. The percentage of non-apoptotic viable cells is shown. Data were corrected for differences in spontaneous cell death.
doi:10.1371/journal.pone.0000559.g002
Anti-CLL Activity of CDDO-Im
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double positive mice were cultured in the presence of various
concentrations of CDDO and CDDO-Im. Both CDDO and
CDDO-Im efficiently induced apoptosis of human (Figure 2A) and
mouse (Figure 2B) CLL/SBL cells. However CDDO-Im was 10-
times more active than CDDO against mouse leukemic cells, and
20-times more active against human CLL cells compared to
CDDO. For mouse TRAF2DN/Bcl-2 B cells the average LD50 for
CDDO-Im was 0.3760.01 mM (n=4), while it was 3.760.3 mM
for CDDO (n=6). In the case of human CLL cells, the average
LD50 for CDDO-Im was 0.0660.017 mM compared to
1.2660.125 mM for CDDO (n=4).
Next, we assessed the efficacy of CDDO and CDDO-Im in vivo.
For these studies, we used TRAF2DN/Bcl-2 mice that have
developed leukemia, as indicated by the presence of a majority of
CLL (FSC
M B220
M) cells in blood (over 4610
6 B cells/ml). Mice
at this stage of the disease already have severe splenomegaly and
lymphadenopathy, and the leukemia progresses over time (2–
4 months) to over 50610
6 CLL B cells/ml [8]. Groups of
TRAF2DN/Bcl-2 mice that had developed leukemia were
injected i.v. with empty liposomes or with liposomes containing
either CDDO (20 mg/Kg) or CDDO-Im, at doses of 5, 10 or
20 mg/kg/day (Table 1 and Figure 3A). Each mouse received
a total of nine injections of a drug administered every 2–3 days
Table 1. Concentration of B cells in blood of TRAF2DN/Bcl2 mice treated with empty liposomes or with triterpenoids.
..................................................................................................................................................
mouse ID Drug B cells (millions)
dosage pre-treatment 1st dosage 2nd dosage 3th dosage 6th dosage post-treatment
Liposomes Day -1 Day 1 Day 2-3 Day 4-6 Day 11-14 Day 24 to 28
310 – 7 89967
327 – 12 nd 10 8.4 8 12
325 – 1 3 1 01 51 31 45 8
420 –6 7 8 n d 7 1 3
414 – 5 55572 7
413 –6 8 1 0 6 2 3 3 4
CDDO
209 20 mg/Kg 26 10 22 21 18 11
332 0 1 4 8 1 11 11 45
190 0 10 12 6 7 4.5 2.4
300 0 41 26 34 45 48 19.6
CDDO-Im
614 5 mg/Kg 32 70 77 35 35 12
615 0 5 9 6.4 9 3.2 1.5
655 0 6.6 9.5 10.6 5.3 7.8 2.3
691 0 48 46 64 73 77 21.6
694 0 9.5 19 17 17 7.5 3.1
711 0 134.7 123 119 140 126 58.5
203 10 mg/Kg 14 63 60 71 dead –
224 0 23 32 24 31 12 2
227 0 13 53 nd 69 dead –
389 0 9 3 94 25 01 03 . 3
314 0 4 2 43 21 52 00 . 6
317 0 7 3 83 22 01 4d e a d
349 0 30 50 47 37 27 0.8
365 0 4.3 21 25 12 5 0.5
382 0 7 1 42 92 0d e a d –
302 20 mg/Kg 26 240 dead – – –
343 0 16 28 72 21 7 1.5
344 0 15 nd 41 15 2 0.6
369 0 23 140 173 118 dead –
388 0 49 105 163 130 dead –
TRAF2DN/Bcl-2 mice were injected i.v. with empty liposomes or with liposomes containing either CDDO or CDDO-Im at doses of 5, 10 or 20 mg/kg/day (corresponding
to 17.3, 34.5 and 69 mg/m
2/day, respectively). Each mouse received a total of nine injections administered over a period of 21–25 days. The concentration of B cells
(610
6/ml) in blood was monitored one day before the inoculation with drug (pre-treatment), after the inoculation of the 1
st,2
nd,3
rd and 6
th drug dosages, and 3 to
10 days after the final inoculation(post-treatment). (nd: not determined).
doi:10.1371/journal.pone.0000559.t001
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PLoS ONE | www.plosone.org 4 June 2007 | Issue 6 | e559over a period of 21–25 days. The concentration and viability of B
cells in blood was monitored the day after each inoculation and 3–
10 days after the end of the treatment. As shown in table 1,
treating TRAF2DN/Bcl-2 mice with empty liposomes had no
significant impact on blood B cell counts or on the normal
progression of the leukemia (8.261.4 vs 26.266.8 millions B cells/
ml before and after the treatment, respectively). In contrast,
CDDO-treated mice (20 mg/Kg) showed a progressive reduction
in the number of B cells in blood throughout the course of the
treatment, with an average 60% reduction in the number of B cells
in blood at the end of the treatment (22.7567 vs 9.563.8 million
B cells/ml before and after the treatment, respectively). In
agreement with the ex vivo data (Fig. 2), the anti-tumor effect of
CDDO-Im in vivo was also significantly greater than CDDO.
Indeed, treatment with 5 mg/Kg CDDO-Im induced a similar
reduction in the number of B cells in blood (average 60%
reduction; 39.4620 vs 16.569) as achieved with 20 mg/Kg
CDDO. Treating mice with 10 or 20 mg/Kg CDDO-Im resulted
in reductions of over 90% of B cells in blood (average 14.563.7 vs
1.360.4 millions B cells/ml before and after the treatment,
respectively) (Figure 3A and B).
CDDO and CDDO-Im treatments also reduced the number of
T cells in blood (Figure 3B). However, while CDDO seems to
reduce the numbers of malignant B cells and normal T cells to
similar extents, CDDO-Im seems to be comparatively more toxic
to mouse leukemic B cells than to normal T cells. Indeed, even at
concentrations of CDDO-Im that reduced 90% of B cells in blood,
T cells (CD4+) are only reduced an average of 30% (Figure 3B).
The limited toxicity of CDDO-Im against normal lymphocytes
was confirmed by treating wild-type mice with 5 and 10 mg/Kg
CDDO-Im, using the same inoculation schedule that was used for
treating the leukemic mice. As shown in Figure 3C, treatment with
5 mg/Kg CDDO-Im had no deleterious effect on normal B and T
levels in blood, while treatment with 10 mg/Kg CDDO-Im
resulted in a moderate 30% reduction in both B and T
lymphocytes in blood. Moreover, treatment of wild-type and
Figure 3. In vivo effect of CDDO and CDDO-Im on CLL/SBL cells and normal lymphocytes (A). Mice with leukemia were treated as indicated. Total
numbers of circulating B cells (B220
+) in blood were quantified 1–2 days before the beginning of the treatment (pre) and 7–10 days after the end of
treatment (post). Statistical significance was determined by Student’s two-tailed paired t-test. (B) Total numbers of circulating B (B220
+) and T (CD4
+)
cells were quantified in blood before and after treatment with empty liposomes (n=5), CDDO (20 mg/Kg; n=5), or CDDO-Im at 5 (n=6) or 10 mg/Kg
(n=9). The ratio of the concentration of cells before and after the treatment was calculated. Figure shows the average percentages 6SEM. (C). Wild-
type mice were treated with 5 or 10 mg/Kg CDDO-Im and the concentration of B (B220+) or T (CD4+) lymphocytes in blood before and after the
treatment was determined. Figure shows the average percentages 6SEM as described in B.
doi:10.1371/journal.pone.0000559.g003
Anti-CLL Activity of CDDO-Im
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which stabilizes or even started to recover by the end of the
treatment (Figure S1).
Furthermore, wild-type and CLL/SBL mice treated with empty
liposomes (vehicle; n=6), CDDO (20 mg/Kg; n=4) or with
5 mg/Kg CDDO-Im (n=8) survived the treatment (Table S1). In
contrast, while a dosage of 10 mg/Kg CDDO-Im was harmless to
wild-type mice (n=7), 44% of CLL/SBL mice (n=9) died during
treatment (Table 1 and Table S1). This result suggests that 10 mg/
Kg CDDO-Im is not intrinsically toxic to mice, and that the
mortality of CLL/SBL mice might be related to the effect of the
drug on the leukemic cells. Finally, 33% of wild-type and 60% of
the leukemic mice treated with 20 mg/Kg CDDO-Im (n=5), died
during treatment (Table 1 and Table S1).
Immunohistochemical analysis of the tissues of mice treated with
CDDO-Im that died during treatment showed evidence of kidney
and liver toxicity, as indicated by hemorragies, cytoplasmic
eosinophilia and vacuolarization in the kidneys, and nuclear
pyknosis, hepatocellular necrosis and acidophilia in the liver (not
shown). These toxic reactions were significantly milder in wild-type
mice or in those mice with leukemia that survived the treatment.
Next, we determined the effect of CDDO-Im on the viability of
blood cells in vivo. These analyses were performed using an assay
based on the alterations in the permeability of cells using
a combination of DNA-binding dyes. As shown in Figure 4A,
CDDO-Im induced massive blood cell death. Dead cells are
already detected after the first dosage of drug, reaching a peak
after the third inoculation with CDDO-Im (Figure 4A). Repre-
sentative examples of cell viability data showing the effect of empty
liposomes and CDDO-Im are shown in Figure 4B.
Those mice that completed the treatment were euthanized 7 to
10 days after the final dosage of drug and tissues were analyzed.
Mice treated with empty liposomes had severe splenomegaly
(14056133 mg, n=7) (Figure 5A) and lymphadenopathy, similar
to untreated TRAF2DN/Bcl-2 mice with overt disease [8]. In
contrast, mice treated with CDDO (20 mg/Kg) showed a signif-
icant reduction in the spleen weight (9376117 mg; n=4), which
was similar to the reduction achieved with 5 mg/Kg CDDO-Im
(839683 mg; n=4). This reduction in spleen weight was even
more striking for mice treated with 10 mg/Kg CDDO-Im
(635671 mg; n=6) (Figure 5A). The spleens of CDDO-Im-
treated mice contained less than 5% the total number of
Figure 4. CDDO-Im induces massive cell death in vivo. A. The percentage of viable (black columns) and apoptotic (dotted columns) cells in the
blood of representative mice after 3 inoculations with empty liposomes or liposomes containing CDDO-Im is shown. Viability was assessed using an
assay based on the alterations in the permeability of cells at different viability stages using a combination of DNA-binding dyes (ViaCount, Guava
Technologies) and a Guava PCA96 fluorometer and analyzed with Guava’s multi-caspase software. B. Representative flow cytometry profile of the
viability of blood cells from mice treated with empty liposomes or liposomes containing CDDO-Im using Viacount (Guava Technologies). Analysis was
performed with Flowjo software (Tree Star, Inc, Ashland, OR). PM2 (red channel) shows nuclear staining of cells using a cell permeable dye. PM1
(yellow-orange channel) shows staining of non-viable cells with a non-cell permeable dye.
doi:10.1371/journal.pone.0000559.g004
Anti-CLL Activity of CDDO-Im
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liposomes (Figure 5B). In addition, CDDO-Im-treated mice
showed little or no residual lymphadenopathy (not shown).
TRAF2DN/Bcl-2 mice with overt disease have an altered
splenic architecture caused by the accumulation of leukemic B
cells and they also have lymphocyte infiltration into several organs.
In particular, mice at the final stages of disease have severe lung
infiltration with development of pleural effusion that seems to be
the ultimate cause of death [8]. Histochemical analysis of spleens
and lungs of TRAF2DN/Bcl-2 mice treated with empty liposomes
demonstrated massive accumulation of CLL/SBL cells in these
organs (Figure 6), similar to that observed in untreated mice with
overt disease. Treatment with CDDO reduced the density of
lymphocytes in spleen and significantly diminished lymphocyte
infiltration in lungs. However, the most striking improvement was
observed in mice treated with CDDO-Im. Histochemical analysis
of spleens of TRAF2DN/Bcl-2 mice with overt disease following
treatment with CDDO-Im showed a dramatic reduction in
resident lymphocytes in spleen, and the lungs of CDDO-Im-
treated mice showed essentially no lymphocyte infiltration by the
end of the treatment (Figure 6).
Remarkably, mice treated with CDDO-Im showed a striking
increase in circulating B cells (B220
+) after the first three CDDO-
Im inoculations, followed by a sustained reduction as the
treatment progressed (Table 1). This effect was more evident in
mice treated with 10 or 20 mg/Kg, but it was also seen in mice
treated with 5 mg/Kg CDDO-Im. In contrast, this increase in
circulating B cells was not observed in mice treated with CDDO
(20 mg/Kg) (Table 1). Altogether, the striking reduction in
resident lymphocytes in spleen, and lungs, and the increase in
circulating leukemic cells in mice treated with CDDO-Im, suggest
that this CDDO-derivative induces mobilization of tumor cells
from lymphoid organs and infiltrated tissues into the circulation.
Finally, FACS analysis of the B cell populations in blood and
spleen of untreated mice and of mice treated with empty liposomes
showed that the majority of cells were CLL/SBL B cells. These
cells are characterized by their medium size and surface expression
of B220
M and CD5
+, which differ from normal B cells that are
small size, have surface B220
H and lack CD5 expression (Figure 7).
Treatment with CDDO resulted in a modest reduction of CLL/
SBL B cells in spleen and blood. However, the most striking
reduction in leukemic B cells in blood and spleen was achieved
with CDDO-Im (Figure 7). Furthermore, and confirming the
results described above (Figure 3), normal B cells were much less
affected by both CDDO and CDDO-Im, remaining readily
detectable in blood and spleen of mice treated with CDDO and
CDDO-Im (Figures 7 and 8).
DISCUSSION
CLL represents the most common type of leukemia. Therefore,
the development of new therapies for CLL patients with refractory
Figure 5. Amelioration of splenomegaly by CDDO and CDDO-Im
treatment. A. TRAF2DN/Bcl-2 mice with leukemia were treated with
empty liposomes or with liposomes containing either CDDO (20 mg/
Kg/day) or CDDO-Im (5 or 10 mg/Kg/day). Mice were euthanized 7–
10 days after the final drug administration, and the spleens were
weighted. The average weight 6SEM of the spleens after the different
treatments was: empty liposomes: 14056133 mg, n=7; CDDO:
9376117, n=4; CDDO-Im (5 mg/Kg): 821683, n=4; and CDDO-Im
(10 mg/Kg): 635671 mg, n=6. Statistical significance of liposomes vs
CDDO (*, p=0.04) and liposomes vs CDDO-Im (5 mg/Kg**, p=0.013;
10 mg/Kg*** p=0.0005) was determined using unpaired t-test. B. Total
number of lymphocytes isolated from spleens of mice treated with
empty liposomes (324644.7610
6; n=3) or with liposomes containing
CDDO-Im (10 mg/Kg) (12.766.7610
6; n=3) is shown.
doi:10.1371/journal.pone.0000559.g005
Figure 6. Histochemical analysis of the spleen and lung of leukemic
mice treated with empty liposomes or liposomes containing CDDO
or CDDO-Im. Tissues and organs from TRAF2DN/Bcl2 leukemic mice
were treated as indicated in the figure. After treatment, tissues were
fixed in Z-fix solution (Anatech Ltd.), embedded in paraffin, and tissue
sections (5 mm) were stained with hematoxylin and eosin (H&E). One
representative example for each treatment is shown. Arrows indicate
the presence of infiltrating lymphocytes.
doi:10.1371/journal.pone.0000559.g006
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been hampered by the difficulties in producing human CLL
xenografts and the absence of animal models that accurately
recapitulate human CLL and that are suitable to be used as
a platform for preclinical testing of new therapies.
We have previously described the generation of a transgenic
mouse model of CLL/SBL. These transgenic mice were
engineered to over-express in B lymphocytes a TRAF2 mutant
that mimics TRAF1 and the anti-apoptotic protein Bcl-2. Both
Bcl-2 and TRAF1 are commonly overexpressed in human CLL B-
cells [7]. These mice develop a disease with remarkable similarities
to human CLL. Furthermore, these mouse CLL/SBL cells are
resistant to apoptosis induced by F-ara-A and dexamethasone. F-
ara-A is used in the treatment of CLL, but patients will eventually
relapse by the selection and expansion of CLL clones refractory to
F-ara-A. Therefore, this mouse model of CLL/SBL recapitulates
some critical aspects of refractory human CLL disease and might
be used as a preclinical model to test the efficacy of new
chemotherapeutic drugs against refractory CLL cells.
In this report, we tested the efficacy of CDDO and its derivative
CDDO-Im both ex vivo and in vivo using human CLL cells and
a transgenic CLL/SBL mouse model. Triterpenoid-derivatives
have shown promise as anti-cancer agents, inducing apoptosis or
inhibiting proliferation of cultured breast [18,21], prostate [19],
lung [19,20], pancreatic [22], ovarian [15,19], colon [16,19],
melanoma [14], leukemia [14,23–25,27,33,34] and myeloma
[17,26,28,35] cell lines. CDDO and derivatives also reduced
tumor burden in vivo in mice bearing human tumor xenografts,
without significant toxicity to normal tissues [13,14,18,21].
Our studies showed that CDDO and its imidazolide derivative
(CDDO-Im) are also potent inducers of apoptosis of human and
mouse CLL cells ex vivo. Moreover, in agreement with previous
reports using other cell types [14,28], CDDO-Im is significantly
more potent than CDDO.
Treating TRAF2DN/Bcl-2 mice with overt disease with
liposomes containing either CDDO or CDDO-Im showed that
both triterpenoids were capable of reducing tumor burden in these
mice. Similar to the results obtained ex vivo, CDDO-Im was also
more potent than CDDO in vivo. CDDO treated mice showed
a significant improvement at the end of the treatment, with amelior-
ation of leukemia, lymphoma, and reduced tumor lymphocyte
infiltration of lungs. However, CDDO-Im had a far more striking
effect in reducing tumor B cells in blood and spleen, which were
reduced to almost normal levels by the end of the treatment. Indeed,
the average spleen weight of TRAF2DN/Bcl-2 mice with overt
disease at the end of the treatment with CDDO-Im was
Figure 7. Analysis of B cell populations in spleen and blood of leukemic mice treated with empty liposomes or liposomes containing CDDO
(20 mg/Kg) or CDDO-Im (10 mg/Kg). Three-color flow-cytometry analysis was performed to determine the phenotype of B lymphocytes. Two
different gates were used to identify normal B cells and CLL/SBL. First, lymphocytes were selected by gating the lymphocyte population in a forward
scattered (FSC) and side scattered (SSC) plot (not shown). Then, B cell populations were identified by plotting B220 expression and FCS. Gate R1
contains cells with high expression of B220 (B220
H) and small size (FSC
L). Red dots within gate R1 were also contained in the lymphocyte gate and
represent normal B cells. Gate R2 includes cells with medium expression of B220 (B220
M) and larger in size (FSC
M). Purple dots within gate R2 were
also contained in the lymphocyte gate and represent CLL/SBL cells. The analysis of the lymphocyte populations expressing B220 and CD5 is also
shown. Representative results are provided for mice that completed the treatment with each drug.
doi:10.1371/journal.pone.0000559.g007
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TRAF2DN/Bcl-2 mice that have not yet progressed to the aggres-
sive leukemic phase of the disease (647654 mg [8]). Moreover,
CDDO-Im-treated mice showed very mild lymphadenopathy or
lymphocyte infiltration into lungs. Altogether, these observations
indicate that CDDO-Im has more potent single agent activity
against CLL/SBL, compared to CDDO, both ex vivo and in vivo.
The long-term benefits of the treatment of CLL/SBL mice with
triterpenoids have been difficult to determine, in part due to the
asynchronous onset of the disease. However, preliminary data with
a small cohort of CLL/SBL mice (n=4) treated with CDDO-Im
indicate that 50% (2/4) of the mice were free of disease for over
8 months after the treatment and were subsequently euthanized.
In contrast, the other two mice relapsed within 4 months after
treatment. Whether additional cycles of treatment might improve
this outcome and increase the life expectancy of the leukemic mice
remains to be determined.
Treatment of leukemic mice with CDDO-Im initially caused an
increase incirculating B cells.Thisphenomenon wasnot observed in
leukemic mice treated with CDDO. The disparity between CDDO
and CDDO-Im might reflect the existence of specific activities for
eachofthese triterpenoids.In this regard,while treatment for several
days with 5 mg/Kg CDDO-Im or 20 mg/Kg CDDO had similar
effects in reducing circulating B cells, the initial increase in
circulating B cells was only observed in CDDO-Im-treated mice.
The most likely source of these new circulating lymphocytes is
spleen, lymph nodes, and tissue-infiltrating lymphocytes, thus
accounting for the striking reduction of lymphocytes in those
compartments. The mechanism involved in the mobilization of
lymphocytes from secondary lymphoid organs and tissues is not
known, but it might be related to the potent anti-inflammatory
activity of CDDO-Im and other triterpenoids [14,36,37]. This
phenomenon might also have an important impact on the anti-
tumor activity of CDDO-Im in vivo, by removing tumor cells from
protective microenvironments and making them more accessible to
conventional chemotherapeutic drugs. Remarkably, CDDO-Im
showed stronger toxicity against leukemic B cells than against
normal B or T cells. This selective anti-tumoral activity of CDDO-
Im has also been observed in other studies [21,26,28], and further
encourages the application of triterpenoids in the clinic
Althoughthemoststrikinganti-leukemiceffectinvivowasachieved
with 10 mg/Kg CDDO-Im, approximately 40% of CLL/SBL mice
receivingthistreatmentdied.Incontrast,wild-typemicetreatedwith
the samedosage ofCDDO-Im survived,suggesting that CDDO-Im-
inducedmortalityisnottheresultofageneraltoxiceffectofthedrug.
We speculate that the massive induction of leukemic cell death by
CDDO-Im might lead to severe kidneys and liver toxicity. However,
we cannot rule out other causes of mortality, for instance a severe
hemodynamicalterationcausedbythesuddenincreaseincirculating
tumor cells induced by CDDO-Im. Optimizing the dosage of
CDDO-Im and/or the administration schedule might help in
reducing lethality while preserving the efficacy of the drug against
CLL/SBL. Indeed, our data suggest that maximal anti-leukemic
activity without associated mortality could be achieved at doses of
CDDO-Im between 5 and 10 mg/Kg. In this regard, it is worth
noting that Phase I clinical trials currently under way show that
CDDO-methyl-ester (CDDO-Me), another CDDO-derivative, is
tolerated without any significant toxicities in stage IV cancer patients
at doses up to 600 mg/day (352 mg/m
2/day) (Colin Meyer, Reata
Pharmaceuticals, personal communication).
Figure 8. Determination of the total number of normal B lymphocytes and CLL/SBL cells in spleen of mice treated with empty liposomes or with
CDDO-Im containing liposomes. The total number of B lymphocytes (CD45
+/B220
+) in spleen was quantified using a cell analysis and
microfluorocytometer (Guava technologies). The percentages of the B220
H FSC
L normal B cells and of the B220
M FSC
M CLL/SBL cells were assessed by
FACS (see Figure 6). The total number of CLL/SBL cells (white) and normal B lymphocytes (grey) in 3 mice treated with 10 mg/Kg CDDO-Im and 3
mice treated with empty liposomes is shown.
doi:10.1371/journal.pone.0000559.g008
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significantly reduce leukemia cells in blood, spleen and lymph
nodes as well as the amount of infiltrating tumor cells in tissues and
organs in a transgenic mouse model of CLL/SBL, thus illustrating
the potential of triterpenoids as novel single agents for the
treatment of CLL.
SUPPORTING INFORMATION
Figure S1 Effect of CDDO-Im on the weight of the mice Wild-
type and TRAF2DN/Bcl-2 mice that have developed CLL/SBL
were treated with a dosage/day of 5 or 10 mg/Kg CDDO-Im.
Mice were injected 9 times over a period of 21 days. Weights were
measured before each inoculation and 2 days after the final dosage
(day 23).
Found at: doi:10.1371/journal.pone.0000559.s001 (0.06 MB
DOC)
Table S1 Lethality associated to the treatment with triterpenoids
Wild-type and TRAF2DN/Bcl-2 mice that had developed CLL/
SBL were treated with CDDO-Im at the indicated dosages. Each
mouse received a total of nine injections administered over a period
of 21–25 days.
Found at: doi:10.1371/journal.pone.0000559.s002 (0.03 MB
DOC)
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